The PST genetic test works by identifying genetic variations that are predictive of severe gum disease and tooth loss in some patients. The test may be used on all ethnic populations and must only be given once in a lifetime to identify at-risk patients. Specifically, the test identifies genetic variants that regulate a protein that when overexpressed, is thought to be associated with destruction of soft tissue attachment and bone and increased severity of gum disease in certain patients.

Interleukin's test can be used in dental offices and is available in all U.S. states including New York, which monitors the accuracy and reliability of results of laboratory tests and sets one of the highest accreditation standards in the country for genetic testing companies. The company hopes the study results establish reimbursement coverage for the test. The insurance company would not have access to any genetic information, Giannobile said. The information would allow the dentist to make a more informed treatment protocol.

An estimated 75 percent of American adults have some form of gum disease, and roughly 20-25 percent have moderate to severe cases which can lead to tooth loss. The year-long study begins in the fall.

Source: University of Michigan